Market Overview
According to fortune business insights, the global molecular modelling market is witnessing significant growth, driven by the rising need for drug discovery and development to combat the increasing incidence of chronic diseases. The market growth is further bolstered by a shift toward personalized medicine and continuous technological advancements. In 2023, North America accounted for the largest share of the global molecular modelling market. While specific market size figures are not provided, biopharma companies spent USD 247 billion on clinical R&D in 2023, a figure projected to rise to USD 285 billion by 2028, indicating a strong underlying demand for molecular modelling tools and services.
This analysis shows that increasing R&D activities and advancements in computational power are accelerating the adoption of molecular modelling. For example, the Journal of Informatics in Medicine Unlocked noted in 2022 that computational capabilities for drug discovery have grown significantly over the last decade, increasing the utilization of these techniques.
Major Players Profiled in the Market Report:
- Schrödinger, Inc. (U.S.)
- Optibrium (U.K.)
- BioSolveIT GmbH (Germany)
- Simulations Plus (U.S.)
- Dassault Systèmes (France)
- NUVISAN GmbH (Germany)
- Rasa Life Science Informatics (Germany)
- Thermo Fisher Scientific, Inc. (U.S.)
- Taros Chemicals GmbH & Co. KG. (Germany)
Segments
Increasing Use in Research to Propel Software Segment Growth
Based on offering, the market is divided into software and services. The software segment is expected to hold a prominent market share due to the increasing focus of drug design labs on conducting studies with molecular modelling software and significant advancements in the software itself.
High Applicability in Biomolecule Simulation to Drive Molecular Mechanics Segment Expansion
By approach, the market is subdivided into quantum mechanics, molecular mechanics, and others. The molecular mechanics segment is expected to hold a major market share due to its primary use in applications such as analyzing drug-macromolecule interactions and its suitability for simulating large biomolecules like proteins and nucleic acids.
Rising R&D Investments to Dominate Drug Development Application Segment
Based on application, the market is fragmented into drug discovery, drug development, and others. The drug development segment is expected to hold a significant market share, driven by rising R&D investments from biopharmaceutical companies to launch new medicines.
Surge in Outsourcing to Boost CDMOs & CROs Segment
By end-user, the market is categorized into pharmaceutical & biotechnology companies, CDMOs and CROs, academic & research institutions, and others. The CDMO & CROs segment is projected to hold a substantial market share, attributed to a surge in the establishment of these organizations and their use of molecular modelling to design and optimize drug candidates.
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
For detailed market insights: https://www.fortunebusinessinsights.com/molecular-modelling-market-111673
Report Coverage
The report offers:
- Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
- Comprehensive insights into regional developments.
- List of major industry players.
- Key strategies adopted by the market players, including mergers, acquisitions, and partnerships.
- The latest industry developments, including new product launches.
- Impact of COVID-19 on the market.
Drivers & Restraints
Increasing Incidence of Chronic Diseases to Boost Market Growth
The significant rise in chronic diseases like cancer, cardiovascular diseases, and neurological disorders is a major market driver. The urgent need for effective treatments highlights the importance of molecular modelling in identifying novel drug candidates and understanding disease mechanisms, fueling market growth. For instance, the WHO estimated 20 million new global cancer cases in February 2024, boosting the need for advanced therapeutic strategies.
However, challenges related to the accuracy and reproducibility of results in drug discovery may hamper market growth. The large system sizes and long timescales required for complex simulations can be a significant hurdle, potentially limiting the full implementation of molecular modelling as a standard practice.
Regional Insights
Increasing R&D Activities in the U.S. Propel Market Growth in North America
North America holds the dominant molecular modelling market share. The region's growth is attributed to increasing R&D activities for drug development, significant investment, and strong regulatory support for these activities, which spurs the demand for molecular modelling software and services in the region.
Asia Pacific is expected to be the fastest-growing region in the market. This growth is attributed to the rising burden of chronic diseases, such as cancer in India, which boosts the demand for drug discovery and the molecular modelling technologies that support it.
Molecular Modelling Market Future Growth
The molecular modelling market is set for robust expansion, driven by ongoing improvements in computational power and software algorithms. The integration of Artificial Intelligence (AI) and Machine Learning (ML) is a key trend, accelerating simulations and enabling researchers to conduct more complex studies with greater speed and accuracy. These advancements are facilitating faster drug development pipelines and supporting the rise of precision medicine tailored to specific genetic profiles. Today’s researchers are increasingly leveraging these sophisticated platforms to optimize lead compounds, make data-driven decisions, and shorten overall development timelines, fueling future market growth.
Competitive Landscape
Fragmented Market with Focus on Strategic Acquisitions to Propel Growth
The global molecular modelling market is fragmented, featuring numerous companies offering specialized software and services. Prominent players like Schrödinger, Inc., Dassault Systèmes, and Simulations Plus are driving growth through strategic initiatives. Key strategies include enhancing software platforms with AI/ML capabilities, expanding service offerings, and pursuing mergers and acquisitions to gain technological advantages and broaden market reach.
Key Industry Development
- October 2024: Terra Quantum AG, in collaboration with RWTH Aachen University, announced a breakthrough in molecular modeling to streamline drug discovery and materials science applications.
- June 2023: Simulations Plus acquired Immunetrics, Inc., a modeling and simulation company focused on accelerating drug development in areas including immunology, oncology, and autoimmune diseases.
What’s Driving Japan’s Market? Discover the Latest Molecular Modelling Market Insights
Comments